Regeneron Stock Forecast: Bullish Long Term Buy For This Undervalued Stock

 

This article was written by Grant Goldstein, a Financial Analyst at I Know First

   

Highlights:

  • Regeneron has Underwhelming Q1 Financials
  • REGN is Undervalued
  • I Know First Bullish Forecast for REGN
I Know First.  

premiumRead The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Winning AVXL Stock Forecast: Life Changing Treatment Discoveries and M&A Expectations Add Value to Avanex

“We are looking forward, focusing on executing clinical trials using the inclusion of advanced genomic biomarkers into late-stage CNS precision medicine trials, including our Rett syndrome, Alzheimer’s disease and Parkinson’s disease dementia trials – all indications with high unmet need”

-Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex.

Anavex Life Sciences Corp. (NASDAQ: AVXL) is a biopharmaceutical company focused on using genetic medicine to treat neurodegenerative and neurodevelopmental diseases, such as Alzheimer’s disease

Read More

Best Pharma Stocks Based On Algorithms: Up to 15.02% Returns in 7 days

Package Name: Pharma Package
Forecast Length: 7 Days (12/15/15 – 12/23/15)
I Know First Average: 8.06%

Read The Full Forecast

Best Pharmaceutical Stocks

Pharmaceutical Stocks To Buy Based On Genetic Algorithms: Up to 15.21% Returns in 14 days

Package Name: Pharma Package
Forecast Length: 14 Days (12/8/15 – 12/22/15)
I Know First Average: 4.68%

Read The Full Forecast

Pharmaceutical Stocks To Buy